SUTRO BIOPHARMA, INC. (STRO): Nasdaq/NYSE listing notice — Sutro Biopharma receives Nasdaq minimum bid price deficiency notice; has until Dec 17, 2025 to cure

SUTRO BIOPHARMA, INC.

Nasdaq notified Sutro on June 20, 2025 of non-compliance with $1.00 minimum bid price rule.
Company has 180 calendar days, until December 17, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.
If not cured, Sutro may transfer to Nasdaq Capital Market for a second 180-day period or face delisting.
Sutro plans to monitor bid price and may implement a reverse stock split if needed.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SUTRO BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

June 20, 2025, Sutro Biopharma, Inc. (the “Company”) received written notice from The NASDAQ Stock Market, LLC (“NASDAQ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until December 17, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-089978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.